
The Clinical Trial Manager (CTM) or Senior Clinical Trial Manager (Sr. CTM) leads the execution of global clinical studies from startup through close-out. The CTM/Sr. CTM partners closely with cross-functional teams and external vendors to deliver high-quality clinical trials on time and within budget while ensuring compliance with regulatory standards. The CTM will independently manage study execution, while the Sr. CTM will lead more complex programs with broader strategic and cross-functional responsibilities.
Clinical Trial Execution
Vendor & CRO Management
Cross-Functional Collaboration
Study Planning & Strategy
Site & Study Oversight
Quality & Compliance
Documentation & Communication
Continuous Improvement
About Lexeo
Lexeo Therapeutics is a clinical-stage genetic medicine company headquartered in New York City, pioneering cardiac genetic medicine candidates to treat the root causes of inherited cardiovascular diseases. Our lead program, LX2006, targets cardiomyopathy associated with Friedreich’s Ataxia and anchors a broader pipeline addressing genetically defined conditions such as hypertrophic and arrhythmogenic cardiomyopathies. Backed by a strong financial foundation, Lexeo is positioned to translate groundbreaking science into durable clinical impact.
Our work culture is a hybrid model with 2 days/week in the New York City office and 3 days working from home.
Lexeo Therapeutics is an EEO employer committed to an exciting, diverse, and enriching work environment.

Based in New York City, Lexeo Therapeutics is a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Building on groundbreaking research from Weill Cornell Medicine and the University of California San Diego, Lexeo partners with preeminent institutions on the cutting edge of gene therapy research. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4 associated Alzheimer's disease programs, and is led by pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing and commercialization.
For more information, please visit www.lexeotx.com.